Medicus Pharma Ltd.(MDCX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MDCX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Medicus Pharma Ltd. (MDCX), a Healthcare sector company. MDCX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Medicus Pharma Ltd. reports net income of $-9.0M, free cash flow of $-9.0M. Top institutional holders of MDCX by reported 13-F value include Interchange Capital Partners,, Private Advisor Group,, ARMISTICE CAPITAL,, based on the most recent SEC filings. MDCX trades on the Nasdaq exchange and files with the SEC under CIK 1997296. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDCX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medicus Pharma Ltd. directly from SEC EDGAR.
Net Income
Q1 2026
$-9.0M
Free Cash Flow
Q1 2026
$-9.0M
D/E Ratio
Q1 2026
1.77
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-323.8% YoYOperating Income
-207.3% YoYEPS (Diluted)
-136.2% YoYTotal Assets
+78.2% YoYTotal Debt
Op. Cash Flow
-122.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-47.3M -323.8% | $-11.2M -109.9% | $-5.3M | — |
| Operating Income | $-34.4M -207.3% | $-11.2M -136.4% | $-4.7M | — |
| EPS (Diluted) | $-2.74 -136.2% | $-1.16 +24.2% | $-1.53 | — |
| Total Assets | $10.1M +78.2% | $5.6M +198.3% | $1.9M | — |
| Total Debt | $5.2M | $0.00 | — | — |
| Operating Cash Flow | $-22.8M -122.3% | $-10.2M -146.4% | $-4.2M | — |
AI Insight: MDCX Financial Trends
Medicus Pharma continues operating losses but Q1 2026 shows stabilizing cash burn and shrinking net losses versus Q3 2025 peak.
• Net income loss narrowed from -$21M (Q3 2025) to -$9M (Q1 2026); operating losses also contracted across same span.
• Operating cash flow stabilized at -$7M to -$9M per quarter since Q3 2025, suggesting burn-rate consistency.
• Total debt remained modest at $2M–$7M range; equity near breakeven, indicating minimal leverage risk currently.
⚠ Company remains unprofitable; no revenue data visible. Path to cash flow positivity and profitability remains unclear.
⚠ Negative equity emerged briefly in Q3 2025 (−$1M). While recovered, signals earlier balance-sheet stress.
AI Insight: MDCX Ratio Trends
Insufficient data to assess operational trends; only leverage ratio available across all periods.
• Debt-to-equity ratio stable at 1.77 in both TTM (Mar 2026) and Q1 2026, indicating consistent capital structure.
⚠ Operating margin, net profit margin, ROE, ROA, and ROIC all missing across Q4 2024–Q1 2026; unable to assess profitability or return trends.
Get alerted when MDCX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Medicus Pharma Ltd. including:
Top Institutional Holders of MDCX
Interchange Capital Partners, LLC
$6.2M1,661,871 shPrivate Advisor Group, LLC
$110.2K240,055 shARMISTICE CAPITAL, LLC
$57.6K60,600 shPrivate Advisor Group, LLC
$27.4K49,000 shWilmington Savings Fund Society, FSB
$23.5K51,244 shMay Hill Capital, LLC
$23.2K50,622 shCOMMONWEALTH EQUITY SERVICES, LLC
$22.1K48,143 shAnson Funds Management LP
$19.5K42,400 shUBS Group AG
$18.6K40,441 shBlackRock, Inc.
$17.1K37,294 sh
| Fund | Value | Shares |
|---|---|---|
| Interchange Capital Partners, LLC | $6.2M | 1,661,871 |
| Private Advisor Group, LLC | $110.2K | 240,055 |
| ARMISTICE CAPITAL, LLC | $57.6K | 60,600 |
| Private Advisor Group, LLC | $27.4K | 49,000 |
| Wilmington Savings Fund Society, FSB | $23.5K | 51,244 |
| May Hill Capital, LLC | $23.2K | 50,622 |
| COMMONWEALTH EQUITY SERVICES, LLC | $22.1K | 48,143 |
| Anson Funds Management LP | $19.5K | 42,400 |
| UBS Group AG | $18.6K | 40,441 |
| BlackRock, Inc. | $17.1K | 37,294 |
More Healthcare Companies
View all Healthcare →Put MDCX on your watchlist
Track score changes the day Medicus Pharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MDCX a good stock to buy?
13F Pro's AI-powered analysis of Medicus Pharma Ltd. (MDCX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDCX are available on the MDCX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MDCX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDCX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medicus Pharma Ltd.'s investment landscape.